As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C
How AM-Pharma turned to European venture investors to fund a Phase III study of recAP to treat acute kidney injury
By Paul Bonanos, Associate Editor | Jul 16, 2019 | 9:05 AM GMT
After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of recAP to treat acute kidney injury.
Read the full 416 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD